Technical Analysis for IMRX - Immuneering Corporation

Grade Last Price % Change Price Change
F 11.7701 -5.08% -0.63
IMRX closed down 4.62 percent on Tuesday, January 18, 2022, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Down
Historical IMRX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -5.08%
NR7 Range Contraction -5.08%
Wide Bands Range Expansion -5.08%
Oversold Stochastic Weakness -5.08%
New 52 Week Closing Low Bearish -9.46%
New 52 Week Low Weakness -9.46%
Wide Bands Range Expansion -9.46%
Oversold Stochastic Weakness -9.46%
Slingshot Bearish Bearish Swing Setup -14.83%
Wide Bands Range Expansion -14.83%
Older End-of-Day Signals for IMRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% 39 minutes ago
60 Minute Opening Range Breakdown about 1 hour ago
1.5x Volume Pace about 1 hour ago
Down 5% about 1 hour ago
Down 3% about 2 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Immuneering Corporation Description

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Solid Tumors Oncology Neuroscience Drug Development Signal Transduction Advanced Solid Tumors Bioinformatics mTOR

Is IMRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 33.6653
52 Week Low 12.23
Average Volume 68,326
200-Day Moving Average 0.00
50-Day Moving Average 21.07
20-Day Moving Average 16.49
10-Day Moving Average 14.20
Average True Range 1.80
ADX 31.93
+DI 9.50
-DI 26.58
Chandelier Exit (Long, 3 ATRs) 18.20
Chandelier Exit (Short, 3 ATRs) 17.63
Upper Bollinger Bands 22.52
Lower Bollinger Band 10.45
Percent B (%b) 0.16
BandWidth 73.18
MACD Line -2.32
MACD Signal Line -2.17
MACD Histogram -0.1507
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.32
Resistance 3 (R3) 14.51 14.06 14.00
Resistance 2 (R2) 14.06 13.57 13.97 13.89
Resistance 1 (R1) 13.23 13.27 13.01 13.04 13.79
Pivot Point 12.78 12.78 12.67 12.69 12.78
Support 1 (S1) 11.95 12.29 11.73 11.76 11.01
Support 2 (S2) 11.50 11.99 11.41 10.91
Support 3 (S3) 10.67 11.50 10.80
Support 4 (S4) 10.48